Please use this identifier to cite or link to this item: https://doi.org/10.1038/gt.2014.11
Title: Intragenic integration in DLC1 sustains factor VIII expression in primary human cells without insertional oncogenicity
Authors: Sivalingam, J.
Phan, T.T.
Kon, O.L. 
Issue Date: 2014
Citation: Sivalingam, J., Phan, T.T., Kon, O.L. (2014). Intragenic integration in DLC1 sustains factor VIII expression in primary human cells without insertional oncogenicity. Gene Therapy 21 (4) : 402-412. ScholarBank@NUS Repository. https://doi.org/10.1038/gt.2014.11
Abstract: Techniques enabling precise genome modifications enhance the safety of gene-based therapy. DLC1 is a hot spot for phiC31 integrase-mediated transgene integration in vitro and in vivo. Here we show that integration of a coagulation factor VIII transgene into intron 7 of DLC1 supports durable expression of factor VIII in primary human umbilical cord-lining epithelial cells. Oligoclonal cells with factor VIII transgene integrated in DLC1 did not have altered expression of DLC1 or neighbouring genes within a 1-Mb interval. Only 1.9% of all expressed genes were transcriptionally altered; most were downregulated and mapped to cell cycle and DNA repair pathways. DLC1-integrated cells were not tumourigenic in vivo and were normal by high-resolution genomic DNA copy number analysis. Our data identify DLC1 as a locus for durable transgene expression that does not incur features of insertional oncogenesis, thus expanding options for developing ex vivo cell therapy mediated by site-specific integration methods. © 2014 Macmillan Publishers Limited.
Source Title: Gene Therapy
URI: http://scholarbank.nus.edu.sg/handle/10635/110142
ISSN: 14765462
DOI: 10.1038/gt.2014.11
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.